Executive Summary
The 11 filings are dominated by annual proxy statements (8 DEF 14A) and merger-related proxies (3 DEFM14A), with a clear split between routine governance and high-stakes corporate events.
The most material developments are the Option Care Health merger (expected close H1 2027), the RREEF Property Trust liquidation plan (no binding asset sales yet), and Wintergreen Acquisition Corp.'s extension request amid a stalled SPAC merger with KIKA Technology. Among operating companies, Shutterstock reported solid FY2025 results—revenue +6% to $989.9M, net income +27% to $45.5M—but its Getty Images merger was terminated on July 7, 2026, removing a key catalyst. Cohu's stock surged 67.8% from March to October 2026, yet PSU grants fell to 396,708 in FY2025 from 202,521 in FY2024 (note: the filing text appears to contain a typo; the trend is likely a decrease from FY2023's 270,073), and the company seeks approval of a new equity plan and a Section 204 ratification to cure a record-date defect. Executive compensation proposals are generally routine, but Anteris Technologies stands out with a large equity package to executives (629,921 RSUs and 800,000 PSUs to the CEO) and 24 proposals, many tied to ASX listing rules. Overall, the proxy season reveals a mix of governance housekeeping, dilution risks (NeoVolta, Reviva), and event-driven situations that warrant monitoring.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: DEF 14A · DEFM14A
Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from November 06, 2026.
Investment Signals (12)
- Shutterstock ↓ (BULLISH)▲
FY2025 revenue grew 6% to $989.9M, operating income +9% to $75.1M, net income +27% to $45.5M, and adjusted EBITDA +10% to $271.8M, demonstrating resilient profitability despite the terminated Getty merger
- Cohu Inc ↓ (BULLISH)▲
Stock rose 67.8% from $28.58 (March 16, 2026) to $47.96 (October 23, 2026), significantly outperforming the broader market, while shares outstanding increased only 0.9%, indicating strong shareholder value creation
- Option Care Health ↓ (BULLISH)▲
Merger with Parent expected to close in H1 2027, providing a potential arbitrage opportunity as the stock may trade at a discount to deal value until regulatory approvals are secured
- Anteris Technologies ↓ (BULLISH)▲
Large equity grants to executives (629,921 RSUs and 800,000 PSUs to CEO Wayne Paterson) align management with long-term performance, signaling confidence in the company's outlook
- Grid Dynamics ↓ (NEUTRAL)▲
Routine proxy with no controversial proposals; stable governance and auditor ratification suggest business as usual, with potential for continued execution
- Reviva Pharmaceuticals ↓ (BEARISH)▲
Seeking a second reverse stock split authorization (1:2 to 1:100) after a 1:20 split in March 2026, indicating persistent share price pressure and potential for further dilution
- NeoVolta ↓ (BEARISH)▲
Proposal to increase authorized shares from 100M to 150M (50% increase) signals likely future dilution, which could pressure the stock
- Wintergreen Acquisition Corp ↓ (BEARISH)▲
Sponsor has ceased funding monthly extension fees ($184,635 per month) and the SEC has not yet declared the S-4 effective, creating significant deal uncertainty
- RREEF Property Trust ↓ (BEARISH)▲
Plan of liquidation with no binding asset sales and no regular distributions going forward; high uncertainty on timing and proceeds
- Vivos Inc ↓ (BEARISH)▲
Series D Preferred carries 43% of total voting power (397M votes out of 923M), concentrating control and potentially limiting influence of common shareholders
- JATT II Acquisition Corp ↓ (NEUTRAL)▲
Business combination with Talawar values the target at $120M, but closing is conditioned on Nasdaq approval and a minimum cash condition, with no operating metrics disclosed
- Cohu Inc ↓ (NEUTRAL)▲
PSU grants fell to 396,708 in FY2025 from 202,521 in FY2024 (likely a typo; trend may be down from FY2023's 270,073), while 3.44M shares remain available under the 2026 Plan, indicating potential dilution but also flexibility for talent retention
Risk Flags (10)
- Wintergreen Acquisition Corp↓ [HIGH RISK]▼
Sponsor will no longer fund monthly extension fees ($184,635), and the SEC has not declared the S-4 effective; multiple redemption opportunities risk pushing net tangible assets below the $5,000,001 closing condition, jeopardizing the KIKA merger
- RREEF Property Trust↓ [HIGH RISK]▼
No binding asset sale agreements and marketing not commenced; company cannot predict if sales will be completed within 24 months, and regular monthly distributions will cease upon approval, creating income uncertainty for shareholders
- Reviva Pharmaceuticals↓ [HIGH RISK]▼
Second reverse stock split authorization within a year (after 1:20 split in March 2026) signals continued share price deterioration and potential for further splits or delisting risk
- NeoVolta↓ [MEDIUM RISK]▼
50% increase in authorized shares (from 100M to 150M) could lead to significant dilution, especially with no financial performance metrics disclosed in the proxy
- Vivos Inc↓ [MEDIUM RISK]▼
Series D Preferred holds 43% of voting power (397M votes), creating governance risk where preferred holders can exert disproportionate influence over common shareholders
- Cohu Inc↓ [MEDIUM RISK]▼
Section 204 ratification to cure a record-date defect; failure to ratify leaves uncertainty unresolved, potentially affecting the validity of prior corporate actions
- Shutterstock↓ [MEDIUM RISK]▼
Getty Images merger terminated on July 7, 2026, removing a major strategic catalyst; the company must now execute on its standalone growth strategy amid competitive pressures
- Option Care Health↓ [MEDIUM RISK]▼
Merger subject to regulatory approvals and stockholder vote; potential delays or litigation could derail the deal, and termination fees may apply
- JATT II Acquisition Corp↓ [MEDIUM RISK]▼
Closing conditioned on Nasdaq listing approval and minimum cash condition; failure to meet these conditions could result in termination and loss of investment
- Anteris Technologies↓ [LOW RISK]▼
24 proposals, many tied to ASX listing rules, create complexity and potential for shareholder confusion; large equity grants could dilute existing holders
Opportunities (10)
- Option Care Health↓ (OPPORTUNITY)◆
Merger arbitrage opportunity as the stock may trade below deal value until closing (expected H1 2027); regulatory approvals and shareholder vote are key catalysts
- Shutterstock↓ (OPPORTUNITY)◆
Despite the terminated Getty merger, FY2025 net income grew 27% and adjusted EBITDA rose 10%, suggesting standalone strength; potential for re-rating if growth continues
- Cohu Inc↓ (OPPORTUNITY)◆
Stock up 67.8% in seven months, but the new 2026 Equity Incentive Plan (with 3.44M shares available) could attract and retain talent, supporting future growth; watch for Section 204 ratification outcome
- Anteris Technologies↓ (OPPORTUNITY)◆
Large equity grants to executives (CEO: 629,921 RSUs + 800,000 PSUs) align incentives and may signal confidence in upcoming milestones; 24 proposals include routine items but also potential for value creation
- Grid Dynamics↓ (OPPORTUNITY)◆
Routine proxy with no controversies; stable governance and auditor ratification suggest smooth operations, with potential for continued execution and growth
- JATT II Acquisition Corp↓ (OPPORTUNITY)◆
Business combination with Talawar at $120M equity value could create a new Nasdaq-listed entity; if closing conditions are met, there may be upside from the combined company
- Wintergreen Acquisition Corp↓ (OPPORTUNITY)◆
If the extension is approved and the SEC clears the S-4, the KIKA merger at $80M valuation could provide a turnaround opportunity, but high risk
- Vivos Inc↓ (OPPORTUNITY)◆
Despite concentrated preferred voting power, the company is seeking approval of a 2026 Omnibus Securities and Incentive Plan, which could align management and drive growth if successful
- Reviva Pharmaceuticals↓ (OPPORTUNITY)◆
If the reverse split authorization is approved and the company executes a successful turnaround, the low share price could offer high-risk/high-reward potential
- NeoVolta↓ (OPPORTUNITY)◆
The increase in authorized shares could support future growth initiatives or acquisitions, though dilution is a concern; watch for strategic announcements
Sector Themes (6)
- SPAC Extension and Redemption Pressures (THEME)◆
Wintergreen Acquisition Corp. faces sponsor fatigue (ceasing $184,635 monthly payments) and SEC delays, reflecting broader SPAC market challenges where extensions are increasingly difficult to secure and redemptions threaten closing conditions
- Reverse Stock Splits as Distress Signals (THEME)◆
Reviva Pharmaceuticals seeks a second reverse split authorization within a year, highlighting ongoing share price pressure in small-cap biotech; similar moves may be seen in other distressed companies
- Equity Plan Dilution (THEME)◆
Cohu (3.44M shares available), NeoVolta (50% authorized share increase), and Anteris (large executive grants) all propose equity expansions, indicating a trend of using stock-based compensation to preserve cash amid uncertain markets
- M&A Activity in Healthcare and Tech (THEME)◆
Option Care Health (healthcare) and JATT II (tech) are pursuing mergers, while Shutterstock's deal fell through; the mixed outcomes suggest a selective M&A environment with regulatory hurdles
- Liquidation and Wind-Down Events (THEME)◆
RREEF Property Trust's liquidation plan reflects stress in certain real estate investment vehicles, with no regular distributions going forward; similar actions may occur in other non-traded REITs
- Concentrated Voting Power (THEME)◆
Vivos Inc.'s Series D Preferred (43% voting power) and Anteris's ASX-listed structure with CDIs highlight governance complexities in small-cap companies, where control can be concentrated
Watch List (8)
- Option Care Health↓ (WATCH)👁
Merger closing expected H1 2027; monitor regulatory approvals and shareholder vote, as any delay could impact arbitrage spreads
- Wintergreen Acquisition Corp↓ (WATCH)👁
Extraordinary General Meeting on November 30, 2026, to vote on extension to May 28, 2028; SEC's declaration of S-4 effectiveness is critical for KIKA merger
- Cohu Inc↓ (WATCH)👁
Section 204 ratification and 2026 Equity Incentive Plan vote at upcoming meeting; failure to ratify could create legal uncertainty
- Shutterstock↓ (WATCH)👁
Annual Meeting on December 22, 2026; watch for management commentary on standalone strategy post-Gettty termination and any new M&A plans
- RREEF Property Trust↓ (WATCH)👁
Stockholder vote on liquidation plan; monitor for any asset sale agreements and timing of distributions
- Reviva Pharmaceuticals↓ (WATCH)👁
Annual Meeting on December 18, 2026; reverse split authorization vote and any updates on financial condition
- Anteris Technologies↓ (WATCH)👁
Annual Meeting on December 2, 2026; 24 proposals including large equity grants; watch for shareholder reaction and any dilution concerns
- JATT II Acquisition Corp↓ (WATCH)👁
Closing conditions include Nasdaq approval and minimum cash; monitor for progress on these fronts and potential termination risks
Filing Analyses
(11)
09-11-2026
Cohu Inc filed a DEF 14A proxy statement seeking stockholder ratification of the 2026 Equity Incentive Plan (adopted March 20, 2026, approved May 15, 2026) and a Section 204 ratification to cure an identified record-date defect; failure to ratify leaves uncertainty from the defect unresolved. The stock rose 67.8% from $28.58 (March 16, 2026) to $47.96 (October 23, 2026), while shares outstanding increased modestly from 46,903,489 to 47,346,050 (+0.9%). PSU grants fell to 396,708 in FY2025 from 202,521 in FY2024 and 270,073 in FY2023, and outstanding awards declined from 2,105,011 to 1,943,023 shares, though 3,441,157 shares remain available for grant under the 2026 Plan versus 1,314,460 previously.
- · PSUs may be earned up to 200% of target based on performance goals
- · 2026 Plan estimated to cover equity awards for approximately three years
- · 2026 Plan prohibits repricing of options/SARs without stockholder approval and contains no evergreen provision, no tax gross-ups, and no liberal change-in-control definition
- · Awards carry a minimum one-year vesting period with limited exceptions
- · Compensation Committee considered dilution, hiring needs, stock price, and ISS guidance in sizing the 2026 Plan
09-11-2026
Option Care Health filed a preliminary DEFM14A proxy statement for a Special Meeting where stockholders will vote on adopting a Merger Agreement under which Merger Sub will merge into the Company, leaving it a wholly owned subsidiary of Parent. The Merger is expected to close in the first half of calendar year 2027, subject to regulatory approvals and the stockholder vote; upon completion, OPCH shares will be delisted from Nasdaq and deregistered under the Exchange Act. The filing details appraisal rights under DGCL Section 262, termination fee obligations on both sides, and risks including potential regulatory delays, litigation, and management disruption; no financial consideration or purchase price is disclosed in this excerpt.
- · Merger expected to close in first half of calendar year 2027, subject to regulatory approvals and stockholder approval
- · Upon closing, OPCH shares will be delisted from Nasdaq and registration under the Exchange Act terminated
- · Company may owe Parent a Company Termination Fee to pursue an alternative transaction; Parent may owe the Company a Parent Termination Fee under certain circumstances
- · Stockholders who do not vote in favor and properly demand appraisal may seek 'fair value' plus interest in Delaware Court of Chancery
- · If the Merger is not completed, the Company remains an independent public company and stockholders receive no payment
- · Proxy solicitor is Innisfree M&A Incorporated, 500 Fifth Avenue, 21st Floor, New York, NY 10110
- · Company operates in one segment (infusion services) with principal offices in Bannockburn, IL
- · Risk factors reference the Form 10-K for fiscal year ended December 31, 2025, filed February 24, 2026
09-11-2026
Shutterstock filed its definitive proxy statement for the 2026 Annual Meeting (virtual, December 22, 2026), asking stockholders to elect Class II directors Timothy Adams and Matthew Salzberg, approve say-on-pay, and ratify PricewaterhouseCoopers as auditor for FY2026. The filing discloses FY2025 results: revenue rose 6% to $989.9 million, income from operations grew 9% to $75.1 million, and net income jumped 27% to $45.5 million, while adjusted EBITDA rose 10% to $271.8 million. However, the previously announced merger-of-equals with Getty Images was terminated on July 7, 2026 after Getty's board resolved not to proceed with the CMA-supervised editorial business sale, removing a major strategic catalyst.
- · Merger Agreement with Getty Images signed January 6, 2025; majority of Shutterstock stockholders approved it at a special meeting on June 10, 2025
- · Getty Images board resolved on June 30, 2026 not to proceed with the CMA-supervised sale of the editorial business and to terminate the Merger Agreement; termination occurred July 7, 2026
- · Record date for the 2026 Annual Meeting is November 2, 2026; meeting opens for entry at 9:45 a.m. ET
- · Proxy materials first mailed on or about November 9, 2026
- · Original 2025 Form 10-K filed February 17, 2026; Form 10-K/A filed April 24, 2026
- · Director nominees to serve three-year terms ending at the 2029 Annual Meeting
- · Common Stock par value $0.01 per share
09-11-2026
Reviva Pharmaceuticals filed a DEF 14A proxy statement for its Annual Meeting to be held virtually on December 18, 2026, with a record date of October 30, 2026 and 13,110,377 shares of common stock outstanding. Stockholders will vote on five proposals: electing five director nominees, ratifying Baker Tilly US, LLP as auditor for FY2026, an advisory say-on-pay vote, and a new authorization for a reverse stock split at a ratio of 1:2 to 1:100 through December 31, 2027. Notably, the company already implemented a 1:20 reverse stock split on March 9, 2026, and is now seeking a second split authorization — a signal of continued share-price pressure. The Board recommends 'FOR' all proposals.
- · Annual Meeting to be held virtually on Friday, December 18, 2026 at 11:00 a.m. Pacific Time via www.virtualshareholdermeeting.com/RVPH2026
- · Record date for voting is October 30, 2026; proxy materials first distributed on or about November 9, 2026
- · Quorum requirement is one-third (1/3) of voting power outstanding on the Record Date
- · A 1-for-20 reverse stock split was already implemented on March 9, 2026, and all share/option/warrant amounts in the proxy are retrospectively adjusted for it
- · New reverse split authorization would allow a ratio from 1-for-2 to 1-for-100 at any time prior to December 31, 2027, at Board discretion without further stockholder approval
- · Baker Tilly US, LLP proposed for ratification as independent auditor for fiscal year ending December 31, 2026
- · Company headquarters: 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014
- · Proxy statement includes pay-versus-performance disclosure and 2025 Summary Compensation Table for named executive officers
09-11-2026
Vivos Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on December 9, 2026, with a record date of November 2, 2026. Stockholders will vote on electing two directors, approving the 2026 Omnibus Securities and Incentive Plan, and ratifying Fruci & Associates II, PLLC as independent auditors for fiscal year 2026. As of the record date, 513,788,110 common shares and multiple preferred series were outstanding, representing 923,804,726 total votes, with Series D Preferred alone carrying 397,063,750 votes (43% of total voting power) at 50 votes per conversion share.
- · Annual Meeting to be held virtually on December 9, 2026 at 11:00 a.m. Pacific Time; registration deadline 11:59 p.m. Eastern Time on December 8, 2026
- · Record Date fixed as November 2, 2026; proxy materials mailed on or about November 9, 2026
- · Series A Preferred carries 5 votes per conversion share, Series B 2 votes, and Series D 50 votes per conversion share
- · Abstentions count as votes AGAINST Proposals No. 2 and 3; broker non-votes have no effect on outcomes
- · Proposals No. 1 and 2 are non-routine matters, so brokers cannot vote uninstructed shares; auditor ratification is routine
- · Board unanimously recommends FOR all director nominees and FOR Proposals No. 2 and 3
- · Company is a Delaware corporation headquartered at 1030 N. Center Parkway, Kennewick, Washington 99336
- · Proxy materials available online at https://web.viewproxy.com/RDGL/2026
09-11-2026
Wintergreen Acquisition Corp. (WTGUU/WTG/WTGUR) filed a DEF 14A proxy for a November 30, 2026 Extraordinary General Meeting seeking to extend its business combination deadline to May 28, 2028 (up to 36 months from its May 28, 2025 IPO) and to eliminate the Sponsor's obligation to fund monthly extension fees of $184,635. The Sponsor has already deposited $553,905 for three monthly extensions (August–November 2026) but has told the Board it will no longer fund monthly deposits. The proposed merger with KIKA Technology INC. values KIKA at $80,000,000, but the deal faces critical uncertainty because the SEC has not yet declared the Form S-4 (Amendment No. 8 filed October 21, 2026) effective, and multiple redemption opportunities risk pushing net tangible assets below the $5,000,001 closing condition.
- · Initial Termination Date was August 28, 2026; Current Maximum Termination Date is May 28, 2027; proposed Extended Date is May 28, 2028
- · Wintergreen incorporated in Cayman Islands on April 29, 2024; IPO closed May 28, 2025
- · Merger Sub formed November 5, 2025; Merger Agreement signed November 17, 2025
- · Form S-4 initially filed April 16, 2026; Amendment No. 8 filed October 21, 2026
- · Next round of SEC comments anticipated after November 4, 2026; next Form S-4 amendment expected mid-December 2026
- · KIKA operates through Hong Kong subsidiary HK TP; Wintergreen will rename to 'KIKA Inc.' upon closing
- · Closing conditions include Nasdaq initial listing approval and $5,000,001 minimum net tangible assets
- · 55,950 Deferred Compensation Shares to be issued to D. Boral Capital LLC at closing
- · Each Right entitles holder to one-eighth (1/8) of one Ordinary Share upon Business Combination
09-11-2026
JATT II Acquisition Corp. filed a DEFM14A proxy statement/prospectus for its business combination with Talawar, announced June 29, 2026, in which Merger Sub will merge into JATT and JATT will survive as a wholly-owned subsidiary of Talawar. Talawar stockholders will receive aggregate equity value of $120,000,000 paid entirely in Post-Closing Company Shares at a deemed value of $10.00 per share, while each outstanding JATT ordinary share converts into one Post-Closing Company Share. Closing is conditioned on Nasdaq listing approval, the Minimum Cash Condition, shareholder approvals and no material adverse effects, with termination rights including an Outside Date and 30-day cure periods; no financial performance or period-over-period operating metrics were disclosed in this excerpt.
- · Business Combination Agreement signed June 29, 2026 between JATT, Merger Sub and Talawar
- · All Talawar Convertible Instruments (including SAFEs) and Preferred Shares convert into Talawar Common Shares immediately prior to the Stock Split
- · Each outstanding and unexercised Talawar Option becomes an Exchanged Option on the same vesting and exercisability terms
- · No fractional Post-Closing Company Shares will be issued; share counts rounded down to the nearest whole share
- · Closing conditions include effectiveness of the Registration Statement, no SEC stop order, Talawar Stockholder Written Consent, Required JATT Shareholder Approval, and conditional Nasdaq listing approval
- · Talawar closing conditions include satisfaction of the Minimum Cash Condition and no JATT Material Adverse Effect
- · Termination permitted by mutual consent, for uncured breaches (30-day cure), or if not consummated by the Outside Date
- · Registration Rights and Lock-Up Agreement must be executed by Talawar stockholders holding 2% or more of shares and by CEO Marc Schegerin
- · JATT is a smaller reporting company/emerging growth company with reduced disclosure obligations
09-11-2026
NeoVolta filed a DEF 14A proxy statement for its 2026 Annual Meeting to be held December 22, 2026, with a record date of October 30, 2026 and 59,103,184 shares of common stock outstanding. Stockholders will vote on electing five directors, ratifying MaloneBailey LLP as auditor for FY2027, approving a new 2026 Stock Plan, and authorizing an increase in authorized common shares from 100,000,000 to 150,000,000. The Board unanimously recommends 'FOR' all proposals; the share authorization increase signals potential dilution, while no financial performance metrics were disclosed in this filing.
- · Annual Meeting scheduled for Tuesday, December 22, 2026 at 10:00 A.M. Pacific Time at 12195 Dearborn Place, Poway, CA
- · Record Date for voting is October 30, 2026
- · Quorum requires one-third of outstanding shares present in person or by proxy
- · Directors elected by plurality of votes cast
- · Auditor ratification requires votes in favor to exceed votes in opposition
- · Proxy materials first sent on or about November 9, 2026
- · Company address: 12195 Dearborn Place, Poway, California 92064
- · Proxy materials available at https://www.cstproxy.com/neovolta/2026
09-11-2026
Anteris Technologies Global Corp. filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders to be held December 2, 2026 (Sydney, with virtual webcast), with a record date of October 29, 2026. Stockholders will vote on 24 proposals, dominated by ASX Listing Rule 10.14/6.23.4 equity approvals: electing David St Denis and Stephen Denaro as Class II directors, ratifying KPMG as auditor for FY2026, and approving a large slate of RSU, PSU and option grants to executives and non-employee directors. The equity package includes 629,921 RSUs to CEO Wayne Paterson, 314,960 RSUs to President David St Denis, 800,000 PSUs to Paterson and 485,000 PSUs to St Denis, plus 1,200,000 option rights to Paterson and 414,000 to St Denis for 2026, alongside director option awards and share/CDI issuances in lieu of cash retainers.
- · Annual Meeting set for December 2, 2026 at 4:00 p.m. Central time (9:00 a.m. AEDT December 3, 2026) at InterContinental Sydney, 16 Phillip Street, Sydney, NSW 2000, Australia, with live webcast at www.virtualshareholdermeeting.com/AVR2026
- · Record date for voting is October 29, 2026 (8:00 a.m. AEDT October 30, 2026)
- · CDI holders may attend but cannot vote electronically or in person at the meeting; they must direct CDN via CDI Voting Instruction Form or www.investorvote.com.au using a 6-digit control number
- · Proxy materials and FY2025 Form 10-K (fiscal year ended December 31, 2025) to be mailed on or about November 9, 2026
- · Proposal Sixteen seeks amendments to terms of previously granted RSUs under the Equity Plan under ASX Listing Rule 6.23.4
- · Proposals Three through Twenty-Three are all conditioned on ASX Listing Rule 10.14 approval for related-party equity grants
09-11-2026
Grid Dynamics Holdings filed a definitive proxy statement (DEF 14A) on November 9, 2026, inviting stockholders to its 2026 Annual Meeting on December 22, 2026, held virtually at 7:30 a.m. Pacific Time. Stockholders of record as of October 26, 2026 will vote on three proposals: electing three Class I directors (Leonard Livschitz, Marina Levinson, Shuo Zhang) for terms through 2029, ratifying Grant Thornton LLP as independent auditor for fiscal year 2026, and a non-binding advisory vote on named executive officer compensation. The Board recommends FOR all three proposals; there were 80,370,851 shares of common stock outstanding and entitled to vote as of the record date.
- · Annual Meeting to be held virtually via live audio webcast at www.virtualshareholdermeeting.com/GDYN2026 on December 22, 2026 at 7:30 a.m. Pacific Time
- · Record date for voting is October 26, 2026; online check-in begins at 7:15 a.m. Pacific Time
- · Proxy materials first mailed on or about November 9, 2026; Annual Report is on Form 10-K for fiscal year ended December 31, 2025, as amended
- · Director election requires a plurality of votes; auditor ratification and say-on-pay require a majority of voting power present
- · Brokers have voting discretion on the routine auditor ratification (Proposal No. 2) but not on director elections or say-on-pay
- · Stockholders are not permitted to cumulate votes in director elections
- · Company headquarters: 6101 Bollinger Canyon Road, Suite 465, San Ramon, CA 94583
09-11-2026
RREEF Property Trust filed a preliminary DEFM14A proxy seeking stockholder approval of a Plan of Liquidation under which it would sell all Company Assets, wind down operations, and distribute proceeds, with the Board authorized to sell assets on any terms without further stockholder approval. As of the proxy date no Company Assets are subject to a binding sale agreement and marketing/sale activities have not commenced, and management warns it cannot predict whether sales can be completed within 24 months of approval, or at all, at assumed prices. If approved, the company does not intend to pay future regular monthly distributions, instead making only discretionary liquidating distributions, with timing and amounts subject to significant uncertainty from costs, buyer defaults, litigation, and reserve adequacy.
- · No Company Assets are subject to a binding sale agreement as of the proxy date, and marketing and sale activities have not yet commenced.
- · Company cannot predict whether asset sales will be completed within 24 months following stockholder approval of the Liquidation Proposal, or at all.
- · If the Liquidation Proposal is approved, the company does not intend to declare or pay future regular monthly distributions, only discretionary liquidating distributions.
- · The Board may amend or terminate the Plan of Liquidation without stockholder approval at any time prior to filing Articles of Dissolution with the Maryland State Department of Assessments and Taxation.
- · Asset sales pursuant to the Plan of Liquidation will not be subject to further stockholder approval unless otherwise required under Maryland law.
- · No lawsuits related to the Plan of Liquidation were pending as of the proxy date, though such litigation is common and could delay or prevent completion.
- · Stockholders may be liable to creditors up to amounts received if the reserve fund or assets transferred to a liquidating trust are inadequate.
- · The company may require additional capital or financing to complete the wind-down, which could reduce amounts available for distribution.
- · Implementation depends on retention of the Advisor's key personnel, with no assurance such personnel will remain in place.
- · The proxy references the Annual Report on Form 10-K for the year ended December 31, 2025 and subsequently filed Quarterly Reports on Form 10-Q.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 11 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Executive Compensation Proxy SEC Filings
November 05, 2026
US Executive Compensation Proxy SEC Filings — November 05, 2026
November 04, 2026
US Executive Compensation Proxy SEC Filings — November 04, 2026
November 03, 2026
US Executive Compensation Proxy SEC Filings — November 03, 2026
November 02, 2026
US Executive Compensation Proxy SEC Filings — November 02, 2026
🇺🇸 More from United States
View all →November 10, 2026
US Pre-Market SEC Filings Roundup — November 10, 2026
US Pre-Market SEC Filings Roundup
November 10, 2026
US Merger & Acquisition SEC Filings — November 10, 2026
US Merger & Acquisition SEC Filings
November 10, 2026
USA Insider Trading Pulse — November 10, 2026
USA Insider Trading Pulse
November 10, 2026
US Corporate Board Director Changes SEC Filings — November 10, 2026
US Corporate Board Director Changes SEC Filings